Loading...
SWTX logo

SpringWorks Therapeutics, Inc.NasdaqGS:SWTX Rapporto sulle azioni

Cap. di mercato US$3.5b
Prezzo delle azioni
US$46.99
US$47
0.02% sottovalutato sconto intrinseco
1Y26.0%
7D0.04%
1D
Valore del portafoglio
​
Vista

SpringWorks Therapeutics, Inc.

Report azionario NasdaqGS:SWTX

Capitalizzazione di mercato: US$3.5b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

SpringWorks Therapeutics (SWTX) Panoramica del titolo

SpringWorks Therapeutics, Inc. è una società biofarmaceutica in fase di sviluppo commerciale, impegnata nello sviluppo e nella commercializzazione di farmaci per le popolazioni di pazienti poco servite affette da malattie rare e tumori. Maggiori dettagli

SWTX analisi fondamentale
Punteggio fiocco di neve
Valutazione0/6
Crescita futura5/6
Prestazioni passate0/6
Salute finanziaria6/6
Dividendi0/6

Premi

Si prevede che gli utili cresceranno del 62.07% all'anno

Analisi del rischio

Non sono stati rilevati rischi per SWTX dai nostri controlli di rischio.

SWTX Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Concorrenti di SpringWorks Therapeutics, Inc.

Storia dei prezzi e prestazioni

Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per SpringWorks Therapeutics
Prezzi storici delle azioni
Prezzo attuale dell'azioneUS$46.99
Massimo di 52 settimaneUS$62.00
Minimo di 52 settimaneUS$28.21
Beta0.70
Variazione di 1 mese0.69%
Variazione a 3 mesi9.10%
Variazione di 1 anno26.05%
Variazione a 3 anni68.66%
Variazione a 5 anni13.23%
Variazione dall'IPO107.64%

Notizie e aggiornamenti recenti

Recent updates

Seeking Alpha • Apr 29

SpringWorks: Acquired By Merck KGaA Based On Rare Tumor Targeting Drugs Like OGSIVEO

Summary Merck KGaA agreed to acquire SpringWorks Therapeutics for $47 per share in cash or for $3.9 billion; the acquisition brings in drugs of OGSIVEO and GOMEKLI to big pharma's pipeline. Expansion opportunities for OGSIVEO include potential European approval for desmoid tumors and trials for relapsed/refractory ovarian granulosa cell tumors. GOMEKLI's approval for NF1-PN patients and ongoing European review further enhance SpringWorks' pipeline value. GOMEKLI is also being explored in a phase 1/2 open-label study to treat pediatric and adult patients with low-grade gliomas. Read the full article on Seeking Alpha
Articolo di analisi • Mar 12

SpringWorks Therapeutics, Inc.'s (NASDAQ:SWTX) Shares Climb 26% But Its Business Is Yet to Catch Up

The SpringWorks Therapeutics, Inc. ( NASDAQ:SWTX ) share price has done very well over the last month, posting an...
Seeking Alpha • Mar 11

SpringWorks Therapeutics: Promising Launches, Expanding Pipeline, And M&A Buzz

Summary SpringWorks Therapeutics portfolio features Ogsiveo for desmoid tumors and Gomekli for NF1‑plexiform neurofibromas. In fact, Ogsiveo’s revenues alone reached $172 million in 2024, supported by orphan drug designations in the US and EU. Similarly, Gomekli is the first FDA-approved MEK inhibitor for NF1‑plexiform neurofibromas, which targets both adults and children. SpringWorks is also working on new potential indications for its IP portfolio while running additional trials and even attracting M&A interest from larger players. In my view, SWTX stock’s valuation has a bit of premium embedded in it, but it looks well deserved. In fact, I believe it’s a good speculative “Buy” at these levels. Read the full article on Seeking Alpha
Seeking Alpha • Jan 13

SpringWorks: PDUFA Review Date Could Lead To Next Approved Pipeline Candidate

Summary SpringWorks has shown strong revenue growth with OGSIVEO, achieving a 23% increase from Q2 of 2024 to Q3 of 2024, and potential EMA approval if it could boost sales further. Mirdametinib, a MEK inhibitor for NF1-PN, has a PDUFA date of February 28th of 2025, and could unlock significant shareholder value if approved. Results from phase 1b study using brimarafenib to treat patients with MAPK mutant solid tumors are expected to be released in the 2nd half of 2025. The company has $498 million in cash as of September 30th of 2024, which is sufficient to fund its operations into the first half of 2026. Read the full article on Seeking Alpha
Seeking Alpha • Dec 31

SpringWorks: With Catalyst On The Horizon And Growing Sales, 2025 Looks Great

Summary SpringWorks Therapeutics shows promising growth with their first approved drug and an imminent second approval for mirdametinib in NF1 treatment. SWTX's financials reveal strong cash reserves and growing sales, though they remain unprofitable, with a net loss of $53.5 million in Q3 2024. Strengths include sustained sales growth and potential back-to-back drug approvals, but risks involve market competition and aggressive goal setting. Despite current valuation concerns, SWTX's fundamentals and potential sales growth justify a "Buy" sentiment for the stock. Read the full article on Seeking Alpha
Seeking Alpha • Dec 15

Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's Top 2 Picks

Summary Jonathan Faison runs the ROTY Biotech Community. Why he's high on Tarsus Pharmaceuticals and his #1 holding, SpringWorks Therapeutics. SpringWorks Therapeutics has promising data with multiple launches planned for next year. Tarsus Pharmaceuticals' lead drug shows strong launch metrics, suggesting significant upside potential despite its current market cap. Read the full article on Seeking Alpha
Articolo di analisi • Nov 15

Here's What Analysts Are Forecasting For SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) After Its Third-Quarter Results

It's been a pretty great week for SpringWorks Therapeutics, Inc. ( NASDAQ:SWTX ) shareholders, with its shares surging...
Seeking Alpha • Nov 04

SpringWorks Therapeutics Merits A Speculative Buy

Summary Since we last visited SpringWorks Therapeutics, Inc. in the summer of 2023, the company has garnered its first FDA approval. That drug has seen encouraging initial sales, and management recently submitted a marketing application for a second candidate. The stock has pulled back recently, even as SpringWorks has funding to get the company to profitability in the years ahead. An updated analysis around SpringWorks Therapeutics follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Aug 07

SpringWorks Therapeutics: Rising On A Strong Post-Launch Quarter, Now Justified As A Buy

Summary SWTX's market confidence has increased post-launch, with $40.2 million in product revenue and $19.5 million in collaboration revenue in the first quarter. Nirogacestat approval for desmoid tumors and potential approval for mirdametinib in 2025 position SWTX well for growth. SWTX's strong commercial execution and expanding product portfolio indicate the potential for profitability and market appreciation. Read the full article on Seeking Alpha
Articolo di analisi • May 11

Need To Know: Analysts Are Much More Bullish On SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Revenues

SpringWorks Therapeutics, Inc. ( NASDAQ:SWTX ) shareholders will have a reason to smile today, with the analysts making...
Articolo di analisi • May 03

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Apr 25

SpringWorks Therapeutics: Newly Commercial Stage, Fully Valued Biotech Means Steer Clear

Summary SpringWorks Therapeutics has received FDA approval for Nirogacestat, marking its entry into the commercial stage biotech industry. The company is now facing the challenge of successfully commercializing its therapy. With rapidly growing losses and its hefty market cap SpringWorks Therapeutics is a "Hold". Read the full article on Seeking Alpha
Seeking Alpha • Apr 19

SpringWorks Therapeutics: Multiple Opportunities, But No Sure-Fire Winners

Summary SpringWorks Therapeutics received FDA approval for its oral gamma secretase inhibitor Ogsiveo for the treatment of desmoid tumors in November last year. Ogsiveo is the first therapy approved for desmoid tumors, with a market opportunity estimated at $2.2 billion. Sales in Q4 2023 were just $5m, however, while net loss was $325m. Ogsiveo could win approval in Europe and also in a new indication Ovarian Granulosa Cell Tumors, opening up larger markets. A second candidate, mirdametinib, may be on track for approval in the rare disease NF-1, and is being evaluated in oncology settings also - as is nirogacestat (Ogsiveo). With more early stage programs, and multiple catalysts in play, some may feel SpringWorks's shares - up over 70% on a 12-months basis - can realise further upside. There is alot of uncertainty, however, which I why I maintain a "hold" rating. Read the full article on Seeking Alpha
Articolo di analisi • Sep 20

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Articolo di analisi • Jun 07

We're Not Very Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • Feb 22

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Articolo di analisi • Nov 09

Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Rendimenti per gli azionisti

SWTXUS BiotechsUS Mercato
7D0.04%1.3%1.4%
1Y26.0%31.4%25.7%

Ritorno vs Industria: SWTX ha superato il US Biotechs che ha restituito 31.4 % nell'ultimo anno.

Rendimento vs Mercato: SWTX ha superato il mercato US che ha restituito 25.7 % nell'ultimo anno.

Volatilità dei prezzi

Is SWTX's price volatile compared to industry and market?
SWTX volatility
SWTX Average Weekly Movement6.4%
Biotechs Industry Average Movement10.5%
Market Average Movement7.2%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Prezzo delle azioni stabile: SWTX non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.

Volatilità nel tempo: La volatilità settimanale ( 6% ) di SWTX è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

FondatoI dipendentiAMMINISTRATORE DELEGATOSito web
2017368Saqib Islamwww.springworkstx.com

SpringWorks Therapeutics, Inc. è un'azienda biofarmaceutica in fase di sviluppo commerciale, impegnata nello sviluppo e nella commercializzazione di farmaci per popolazioni di pazienti poco servite affette da malattie rare e tumori. L'azienda offre OGSIVEO (nirogacestat), un inibitore orale di piccole molecole della gamma secretasi per il trattamento dei tumori desmoidi, e GOMEKLI (mirdametinib), un inibitore orale di piccole molecole di MEK1 e MEK2 per il trattamento di pazienti adulti e pediatrici di età pari o superiore a due anni con neurofibromi plessiformi associati alla neurofibromatosi di tipo 1 (NF1-PN). L'azienda sviluppa anche Nirogacestat, in fase di sviluppo clinico di Fase 2 come monoterapia per il trattamento dei tumori ovarici a cellule della granulosa (GCT), un sottotipo di tumore ovarico, e mirdametinib per il trattamento di tumori solidi che presentano altre aberrazioni MAPK, compreso il trattamento di pazienti pediatrici e giovani adulti con gliomi a basso grado, che è in fase di sperimentazione clinica di Fase 1/2.

SpringWorks Therapeutics, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di SpringWorks Therapeutics con la sua capitalizzazione di mercato?
SWTX statistiche fondamentali
Capitalizzazione di mercatoUS$3.54b
Utili (TTM)-US$253.93m
Ricavi(TTM)US$219.67m
16.1x
Rapporto P/S
-13.9x
Rapporto P/E

SWTX è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Utili e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
SWTX Conto economico (TTM)
RicaviUS$219.67m
Costo del fatturatoUS$14.88m
Profitto lordoUS$204.80m
Altre speseUS$458.73m
Utili-US$253.93m

Ultimi utili riportati

Mar 31, 2025

Prossima data di guadagno

n/a

Utile per azione (EPS)-3.37
Margine lordo93.23%
Margine di profitto netto-115.60%
Rapporto debito/patrimonio netto0%

Come si è comportato SWTX nel lungo periodo?

Vedi performance storica e confronto

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2025/07/02 07:50
Prezzo dell'azione a fine giornata2025/06/30 00:00
Utili2025/03/31
Utili annuali2024/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

SpringWorks Therapeutics, Inc. è coperta da 4 analisti. 3 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Cory KasimovEvercore ISI
Corinne JohnsonGoldman Sachs
Michael SchmidtGuggenheim Securities, LLC